drugset / Trial / NCT00656981

Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne

NCT00656981

Phase 3 Completed 541 enrolled Bayer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objectives of this study were to evaluate the efficacy and safety of drospirenone 3 mg/ethinyl estradiol 0.02 mg (DRSP/EE) in comparison with placebo in female subjects with moderate acne vulgaris during 6 treatment cycles

Timeline

Start
2003-01
Primary completion
Completion
2004-06

Drugs

EvaluationDrugModalityDoseRoute
Subject drospirenone Unknown 3 mg Oral
Subject ethinyl estradiol Small molecule 0.02 mg Oral

Indications